Amplitude Unveils New Experimentation Application for Digital Optimization
10.6.2021 12:54:00 EEST | Business Wire | Press release
Amplitude’s Virtual Digital Disruptors Summit — Amplitude, the Digital Optimization System, today introduced Amplitude Experiment, the industry’s first experimentation solution powered by customer behavior and product analytics. Amplitude Experiment provides organizations an end-to-end experimentation and delivery workflow that integrates customer data into every step from generating a hypothesis to targeting users to measuring results. Organizations are empowered to run higher impact A/B tests and remotely configure experiences for key segments without incremental engineering work.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210610005437/en/
New Amplitude Experiment product leverages customer behavior and product analytics to eliminate the barriers to scaling A/B testing programs (Graphic: Business Wire)
“Every company needs to be digital first, but too many are guessing what they should build next and wasting time on experiments that are doomed to fail,” said Justin Bauer, SVP Product, Amplitude. “Since Experiment is powered by customer behavior, businesses can free themselves from low-impact activities and get the invaluable insight that can accelerate and truly scale how they design and deliver digital products and experiences. This is an entirely new chapter for A/B testing that enables any company - whether they’re digital native or embarking on their digital transformation journey - to make bigger and smarter bets that drive stronger business results.”
Digital growth and customer loyalty are driven by how quickly organizations can determine and deliver the best experience for customers. However, existing solutions for A/B testing and feature flagging make it difficult to scale experimentation and rapid learning because they are disconnected from customer behavior. This gap means they lack both the analytics to design effective experiments and surface clear next steps and the behavioral data to target segments and manage user identity. The result is organizations get stuck in low-value activities that don’t drive growth - like testing small tweaks to copy and color changes or using basic on/off toggling to manage new feature release risk - or they waste resources and time on experiments that are doomed to fail - like starting from a weak hypothesis or not being able to reach the right segments.
Through the Behavioral Graph and Amplitude’s Digital Optimization System, Amplitude Experiment eliminates these challenges by resolving the underlying issues of experiment design, targeting, identity resolution and analysis. Now with the addition of the Amplitude Experiment solution, organizations have a complete learning and growth loop from insight to action to testing and delivery all within a single system.
- Amplitude Analytics identifies problems, uncovers opportunities, and measures impact.
- Amplitude Recommend matches the right messages, content, and items to each individual user.
- Amplitude Experiment tests bets and serves the best experience to customers.
“Our digital experience is core to the success of our business - the speed at which we experiment and test new features is critical. Amplitude Experiment is a game changer for Shift. Since it’s powered by customer behavior insights and analytics, we’re able to design better tests, learn from them faster and change the way we build and deliver experiences to our customers”, said Adam Johnston, Director of Product at Shift. “Amplitude has been a great partner to Shift on product analytics, and we are excited to have been able to deepen that relationship through the new Experiment product.”
Experiment is available now. To learn more please visit: amplitude.com/amplitude-experiment and to watch a short video visit: https://www.youtube.com/watch?v=eV4LAKXutqw
About Amplitude
Amplitude is the Digital Optimization System. Powered by the proprietary Amplitude Behavioral Graph, the Digital Optimization System enables organizations to see and predict which combination of features and actions translate to business outcomes — from loyalty to lifetime value — and intelligently adapt each experience in real time based on these insights. Amplitude is the brain behind more than 45,000 digital products at over 1,000 enterprise customers, including 23 of the Fortune 100, helping them innovate faster and smarter by answering the strategic question: “How do our digital products drive our business?” Learn more at https://amplitude.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210610005437/en/
Contact information
Kerry Rothery
Clarity PR for Amplitude
press@amplitude.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom